COLLEGIUM PHARMACEUTICAL INC (COLL)
US19459J1043 - Common Stock
Taking everything into account, COLL scores 6 out of 10 in our fundamental rating. COLL was compared to 198 industry peers in the Pharmaceuticals industry. COLL has an excellent profitability rating, but there are some minor concerns on its financial health. COLL may be a bit undervalued, certainly considering the very reasonable score on growth This makes COLL very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year COLL was profitable.
COLL had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: COLL reported negative net income in multiple years.
In the past 5 years COLL always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of COLL (4.21%) is better than 89.23% of its industry peers.
COLL's Return On Equity of 24.63% is amongst the best of the industry. COLL outperforms 93.85% of its industry peers.
COLL's Return On Invested Capital of 16.27% is amongst the best of the industry. COLL outperforms 92.82% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for COLL is significantly below the industry average of 16.38%.
The 3 year average ROIC (8.70%) for COLL is below the current ROIC(16.27%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.21% | ||
| ROE | 24.63% | ||
| ROIC | 16.27% |
ROA(3y)4.14%
ROA(5y)1.83%
ROE(3y)15.68%
ROE(5y)7.1%
ROIC(3y)8.7%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of COLL (8.49%) is better than 88.21% of its industry peers.
In the last couple of years the Profit Margin of COLL has remained more or less at the same level.
With an excellent Operating Margin value of 30.95%, COLL belongs to the best of the industry, outperforming 95.90% of the companies in the same industry.
In the last couple of years the Operating Margin of COLL has grown nicely.
COLL has a Gross Margin of 57.54%. This is in the better half of the industry: COLL outperforms 65.13% of its industry peers.
COLL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.95% | ||
| PM (TTM) | 8.49% | ||
| GM | 57.54% |
OM growth 3Y19.53%
OM growth 5YN/A
PM growth 3Y-0.58%
PM growth 5YN/A
GM growth 3Y-0.26%
GM growth 5Y7.07%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so COLL is still creating some value.
The number of shares outstanding for COLL has been reduced compared to 1 year ago.
COLL has less shares outstanding than it did 5 years ago.
The debt/assets ratio for COLL has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.58, we must say that COLL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of COLL (1.58) is better than 64.62% of its industry peers.
COLL has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as COLL would need 2.43 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.43, COLL belongs to the top of the industry, outperforming 92.82% of the companies in the same industry.
COLL has a Debt/Equity ratio of 2.48. This is a high value indicating a heavy dependency on external financing.
COLL has a Debt to Equity ratio of 2.48. This is amonst the worse of the industry: COLL underperforms 81.54% of its industry peers.
Even though the debt/equity ratio score it not favorable for COLL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.48 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 1.58 |
ROIC/WACC1.8
WACC9.04%
2.3 Liquidity
COLL has a Current Ratio of 1.17. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.17, COLL is not doing good in the industry: 83.59% of the companies in the same industry are doing better.
A Quick Ratio of 1.10 indicates that COLL should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.10, COLL is doing worse than 77.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 110.71% over the past year.
COLL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.79% yearly.
Looking at the last year, COLL shows a very strong growth in Revenue. The Revenue has grown by 22.17%.
The Revenue has been growing by 15.11% on average over the past years. This is quite good.
EPS 1Y (TTM)110.71%
EPS 3Y15.79%
EPS 5YN/A
EPS growth Q2Q490.48%
Revenue 1Y (TTM)22.17%
Revenue growth 3Y22.28%
Revenue growth 5Y15.11%
Revenue growth Q2Q15.54%
3.2 Future
COLL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.76% yearly.
Based on estimates for the next years, COLL will show a decrease in Revenue. The Revenue will decrease by -6.60% on average per year.
EPS Next Y155.22%
EPS Next 2Y78.11%
EPS Next 3Y56.57%
EPS Next 5Y37.76%
Revenue Next Year3.31%
Revenue Next 2Y2.71%
Revenue Next 3Y0.02%
Revenue Next 5Y-6.6%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 31.79 indicates a quite expensive valuation of COLL.
Compared to the rest of the industry, the Price/Earnings ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 82.05% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 28.28. COLL is around the same levels.
Based on the Price/Forward Earnings ratio of 12.46, the valuation of COLL can be described as correct.
COLL's Price/Forward Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 90.26% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of COLL to the average of the S&P500 Index (20.88), we can say COLL is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.79 | ||
| Fwd PE | 12.46 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, COLL is valued cheaply inside the industry as 96.92% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 96.92% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.47 | ||
| EV/EBITDA | 4.66 |
4.3 Compensation for Growth
COLL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
COLL has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as COLL's earnings are expected to grow with 56.57% in the coming years.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y78.11%
EPS Next 3Y56.57%
5. Dividend
5.1 Amount
No dividends for COLL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
COLLEGIUM PHARMACEUTICAL INC
NASDAQ:COLL (5/3/2024, 7:00:00 PM)
After market: 37.51 0 (0%)37.51
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.23B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.79 | ||
| Fwd PE | 12.46 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.2
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.21% | ||
| ROE | 24.63% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 30.95% | ||
| PM (TTM) | 8.49% | ||
| GM | 57.54% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.48 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)110.71%
EPS 3Y15.79%
EPS 5Y
EPS growth Q2Q
EPS Next Y155.22%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.17%
Revenue growth 3Y22.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y